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Background: Repeated exposure to peritoneal dialysis (PD) solutions contributes to cumulative intraperitoneal
inflammation and peritoneal injury. The present study aimed to explore the capacity of dialysate interleukin-6(IL-6)
to a) predict peritoneal membrane function and peritonitis in incident PD patients, and b) to evaluate the influence
of neutral pH, low glucose degradation product (GDP) PD solution on dialysate IL-6 levels.
Methods: The study included 88 incident participants from the balANZ trial who had completed 24-months of
follow-up. Change in peritoneal solute transport rate (PSTR) and peritonitis were primary outcome measures, and
the utility of IL-6 and IL-6 appearance rate (IL-6 AR) in predicting these outcomes was analyzed using multilevel
linear regression and Cox proportional hazards models, respectively. Sensitivity analyses were performed by
analyzing outcomes in a peritonitis-free cohort (n = 56).
Results: Dialysate IL-6 concentration significantly increased from baseline to 24 months (mean difference 19.07 pg/mL;
P < 0.001) but was not affected by the type of PD solution received (P = 0.68). An increase in PSTR from baseline
was associated with higher levels of IL-6 (P = 0.004), the use of standard solutions (P = 0.005) and longer PD duration
(P < 0.001). Baseline IL-6 level was not associated with a shorter time to first peritonitis (adjusted hazard ratio 1.00,
95% CI 0.99-1.00, P = 0.74). Analysis of IL-6 AR as well as sensitivity analyses in a peritonitis-free cohort yielded
comparable results.
Conclusion: Dialysate IL-6 concentration increased with longer PD duration and was a significant, independent
predictor of PSTR. The use of biocompatible PD solutions exerted no significant effect on dialysate IL-6 levels but did
abrogate the increase in PSTR associated with standard PD solutions. This is the first study to examine the
impact of biocompatible solutions on the utility of IL-6 in predicting PSTR and peritonitis.
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The peritoneum is composed of a monolayer of mesothelial
cells resting upon a thin basement membrane [1,2]. Con-
tinuous exposure to conventional peritoneal dialysis (PD)
solutions contributes to progressive peritoneal injury, is an
important source of local inflammation that can result in* Correspondence: david.johnson2@health.qld.gov.au
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stated.adverse functional outcomes, such as higher peritoneal sol-
ute transport rate (PSTR), a widely accepted risk factor for
mortality and technique failure in PD patients [3-5].
Interleukin-6 (IL-6) is an immuno-modulatory cyto-
kine that plays a critical role in many innate and ac-
quired inflammatory processes [6]. It is secreted in large
quantities by peritoneal mesothelial cells in response to
inflammatory stimuli and modulated by exposure to PD
solutions [7]. Interest in IL-6 and its role in intraperito-
neal inflammation in PD patients is increasing as a result
of the link from single centre studies to changes in PSTR,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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from the large multicenter GLOBAL study [8-10]. To date
there are no data on the impact of biocompatible PD
solution use on IL-6 levels and its relationship to PSTR.
Improvement in peritoneal membrane morphology from
the use of more biocompatible solutions, characterized
by neutral pH with lowered glucose degradation product
(GDP), has been suggested previously [11,12]. Therefore,
its use may lead to changes in the intraperitoneal in-
flammatory milieu with potential benefits to peritoneal
membrane function and improved host defence against
peritonitis. Although a number of randomized controlled
trials (RCT) have reported comparable dialysate IL-6
levels from biocompatible and standard solutions use
[13-16], these studies were limited by open and variable
prescription, large drop out rates (>20%) [16], cross-over
study designs with the risk of carry-over effect [14], risk of
bias from including biocompatible solutions with variable
GDP levels in the treatment group [15], and a lack of ac-
counting for the confounding effect of peritonitis [13-16].
The utility of dialysate IL-6 as a potential predictor of ad-
verse peritoneal membrane function has not been studied
within an RCT setting.
The aims of the present study were to describe the trend
in dialysate IL-6 concentration and IL-6 appearance rate
(IL-6 AR) in incident PD patients, to explore the utility of
dialysate IL-6 as a predictor of PSTR and peritonitis in this
patient group and to evaluate the impact of neutral pH,
low GDP PD solutions on these outcomes.
Methods
Study design
Data were obtained from the participants of the balANZ
trial [17]. Detailed description of the study design and
methodology has been previously published [18], as have
the results of the main primary and secondary analyses
[17,19,20]. The trial was registered with the Australian New
Zealand Clinical Trials Registry (ACTRN12606000044527).
The study protocol was approved by the ethics committees
at Princess Alexandra Hospital Research Ethics Committee
as well as all other participating units (see Appendix for
list of hospitals). All patients provided written informed
consent prior to trial participation, including consent to
biomarker studies using stored samples. Incident, adult
PD patients who had commenced dialysis for the first time
within the preceding 90 days with both a residual measured
glomerular filtration rate (GFR) ≥5 ml/min/1.73 m2 and a
measured urine volume ≥400 ml/day at enrolment were
included in the study. Pregnant or breastfeeding patients,
individuals expected to die within 12 months, patients
participating in trials targeting residual renal function in
PD or those with a significant cancer history in the past
5 years, acute infection at enrolment, contra-indications
to PD, any physical or mental disorder that appreciablyhampered study protocol compliance or known or sus-
pected allergy to trial product or related products were
excluded. Of the 185 participants of the balANZ trial,
88 participants who had completed 24-month follow-up
(Balance® n = 42; Stay.Safe® n = 46) with at least one PD
effluent (PDE) sample stored during trial participation
were included in the present investigation.
IL-6
PDE samples were collected at baseline, 12, and 24 month
visits. PDE was initially stored in a −20°C or −80°C freezer
locally, then transported frozen to a central storage facility
and kept at −80°C. Samples were thawed once only during
the aliquoting process prior to analysis. IL-6 was measured
by an electrochemiluminescence immunoassay technique
using the manufacturer’s protocols. 96-well plates meas-
uring IL-6 were analysed on a Sector Imager 6000®
(Mesoscale Discovery [MSD], Gaithusburg, MD, USA).
Samples and standards were analysed in duplicates with
a maximum tolerated coefficient of variation (CV) of
20%. The lower level of detection limit was 0.07 pg/mL.
No inter-assay CV was determined as all samples from
an individual were run at the same time to minimize
between-assay variability.
Clinical outcomes
The clinical outcome measures were: 1) PSTR defined as
4 hour dialysate:plasma creatinine ratio (DPcr4h) measured
during the peritoneal equilibration test (PET), and 2) epi-
sodes of PD-related peritonitis during study participation.
Calculations
IL-6 AR was calculated by multiplying the PDE IL-6
concentrations and drained volume, which was then
divided by the dwell time and expressed as picograms
per minute. To account for individual variation in baseline
IL-6 concentrations and peritoneal functional capacity,
the change in IL-6, IL-6 AR, and PSTR were calculated
for month 12 (month 12 – baseline); and month 24
(month 24 – baseline). Baseline values of PSTR were
measured at month 1.
Statistical analyses
Results were expressed as frequencies (percentages) for
categorical variables, mean ± standard deviation (SD)
for continuous normally distributed variables, and me-
dian (interquartile range) for continuous non-normally
distributed variables. Differences between groups on
baseline characteristics were analysed by χ2 test for
categorical data, t-test or Mann–Whitney U test for
continuous data, as appropriate. The overall trend in
IL-6 concentrations and IL-6 AR were analysed by fit-
ting a multilevel linear regression model to the log-
transformed IL-6 data (or IL-6 AR). Categorical time
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effect and random intercepts and slopes were added to
allow for repeated measurements over time. To evalu-
ate the differences between the two treatment groups
on IL-6, PD solution type (Biocompatible vs. Control)
and the interaction between solution type and time
were subsequently added to the model as fixed effects.
If the interaction term was not statistically significant,
the unconditional effects of PD solution type on IL-6
would be retained and the interaction term was re-
moved from the final model. In addition, the baseline
IL-6 or IL-6 AR were explored as potential predictors
of change in their respective post-baseline levels. The
IL-6 and IL-6 AR data were log transformed due to their
non-normal distributions. As a sensitivity analysis, the role
of loss of residual renal function (calculated by GFR at
relevant month – baseline value) on IL-6 concentrations
over time was explored as a time-varying covariate in
the multilevel linear regression model.
To determine whether IL-6 was associated with changes
in PSTR, a multilevel linear regression model was fitted.
Clinically recognized risk factors that affect PSTR (such as
time on PD, racial origin, age, body mass index [BMI],
male gender) [21,22] and randomly assigned type of PD
solution [19] were included as fixed-effects in an initial full
model. Variables with statistically non-significant effects in
the full model were removed from the final model. The fit
of the final model was checked against the full model using
the likelihood ratio test. Any significant interaction identi-
fied was added to the model. Due to the potential bias in-
troduced by peritonitis-related increase in IL-6 and PSTR,
a sensitivity analysis in a subgroup who were peritonitis-
free was performed (biocompatible n = 34; control n = 22).
Time to first peritonitis was analyzed by a multivariable
Cox proportional hazards model. Baseline IL-6, PD solu-
tion type, age, sex, racial origin, BMI, diabetes mellitus,
PD modality (automated PD/continuous ambulatory PD)
were explored as covariates. Baseline IL-6 was chosen in-
stead of IL-6 from each visit because of the cause-and-
effect relationship between IL-6 and peritonitis. Patients
who experienced peritonitis prior to the first PDE col-
lection were excluded from the analysis (n = 3). Data
were analysed using the software package Stata/SE12.0
(College Station, TX). P < 0.05 was considered to repre-
sent statistically significant differences.
Results
Patient characteristics
The patients (biocompatible n = 42; control n = 46) were
well matched for all baseline characteristics other than
higher peritoneal ultrafiltration (P = 0.03) and lower PSTR
(P = 0.006) at one month in the control group (Table 1).
The baseline characteristics of this subgroup were com-
parable to the original balANZ trial cohort [17].The trend of dialysate interleukin-6 concentrations
There was a statistically significant increase in median
IL-6 concentrations over time from 7.22 pg/mL at baseline
to 31.35 pg/mL at month 24 (P < 0.001, Figure 1). Similar
trajectories were observed for the biocompatible and
control groups (P = 0.68; Figure 2). There was no signifi-
cant interaction between the type of PD solution received
and time on PD (P = 0.09; data not shown). PD duration
remained a significant and independent predictor of IL-6
after the type of PD solutions received was added to the
model (Table 2). There was no significant association
between loss of residual renal function and the time
trend in dialysate IL-6 concentrations (P = 0.67).
Change in IL-6 concentration from baseline was com-
parable at 12 and 24 months (P = 0.12) but was negatively
associated with baseline IL-6 levels (coefficient −0.88, P
< 0.001; Additional file 1: Figure S1). A sensitivity analysis
excluding an outlier produced comparable results (coeffi-
cient −0.88, P < 0.001). Similar results were obtained
when analyses were repeated in the peritonitis-free co-
hort (Table 2) as well as when IL-6 AR (Additional file
1: Table S1) was analysed as the outcome.
Interleukin-6 as predictor of peritoneal membrane function
Change in PSTR from baseline was significantly greater
in those with higher levels of IL-6 (P = 0.004), who had
received standard PD solutions (P = 0.005), and over
longer PD duration (P < 0.001). The two-way interaction
between PD duration and PD solution type was signifi-
cant (P = 0.007), such that patients who received
standard solutions experienced a greater increase in
PSTR with longer PD duration whilst those who re-
ceived biocompatible solutions maintained a relatively
stable PSTR over time (Table 3; Additional file 1: Fig-
ure S2). A sensitivity analysis in the peritonitis-free co-
hort produced similar results (Additional file 1: Table
S2) except that the effect of standard solutions on
PSTR was no longer statistically significant (P = 0.06).
Baseline interluekin-6 as predictor of peritonitis
Twenty-nine patients (biocompatible n = 5; control n = 24)
experienced 45 episodes of peritonitis during the study.
Peritonitis rates, expressed as episodes per patient-year,
were 0.27 (95% confidence interval [95% CI] 0.19-0.36)
overall, 0.10 (95% CI 0.04-0.20) in the biocompatible
group, and 0.41 (95% CI 0.29-0.56) in the control group.
The majority of patients experienced their first peritonitis
in the first 12 months of the study (77.8%). Baseline me-
dian dialysate IL-6 levels in patients who experienced peri-
tonitis against those who never experienced peritonitis
were, 7.87 pg/mL and 5.75 pg/mL, respectively (P = 0.15).
According to a multivariable Cox proportional hazards
model analysis, standard solution use (biocompatible solu-
tion: adjusted hazard ratio [AHR] 0.19, 95% CI 0.07-0.50;
Table 1 Baseline characteristics
Characteristic Total (n=88) Biocompatible (n=42) Control (n=46) P values
Age (yr) 62 (51–69) 64 (51–70) 60 (51–67) 0.28
Female 39 (44.32) 18 (42.86) 21 (45.65) 0.79
Ethnicity 0.21
- Caucasian 65 (73.86) 34 (80.95) 31 (67.39)
- ATSI 3 (3.41) 1 (2.38) 2 (4.35)
- Asian 16 (18.18) 7 (16.67) 9 (19.57)
- MPI 4 (4.55) 0 (0) 4 (8.69)
Diabetes Mellitus 28 (31.82) 12 (28.57) 16 (34.78) 0.53
Primary renal disease 0.16
- Glomerulonephritis 21(23.86) 9 (21.43) 12(26.09)
- Diabetic nephropathy 22 (25.00) 7 (16.67) 15 (32.61)
- Hypertensive/Renovascular 15 (17.05) 7 (16.67) 8 (17.39)
- Polycystic kidney disease 8 (9.09) 5 (11.90) 3 (6.52)
- Reflux nephropathy 4 (4.55) 4 (9.52) 0 (0.00)
- Other 18 (20.45) 10 (23.81) 8 (17.39)
Body mass index (kg/m2) 0.54
- <20 2 (2.27) 0 (0) 2 (4.35)
- 20-24.9 25 (28.41) 13 (30.95) 12 (26.09)
- 25-30 32 (36.36) 16 (38.10) 16 (34.78)
- >30 29 (32.95) 13 (30.95) 16 (34.78)
Haemodialysis before PD 4 (4.55) 2 (4.76) 2 (4.35) 0.93
Initial PD modality 0.79
- CAPD 81 (92.05) 39 (92.86) 42 (91.30)
- APD 7 (7.95) 3 (7.14) 4 (8.70)
GFR (mL/min per 1.73 m2) 7.40 ± 2.85 7.28 ± 2.58 7.51 ± 3.09 0.72
Urine volume (mL/day) 1379.50 (1057.5-1900) 1573 (1060–2059) 1325 (1055–1810) 0.25
7.5% Icodextrin use (%) 11 (12.50) 5 (11.90) 6 (13.04) 0.87
Ultrafiltration# (mL/day) 959.50 (510–1400) 800 (430–1300) 1050 (773–1500) 0.03
Normalized ultrafiltration corrected for total glucose exposure# 4.08 (2.21-6.04) 3.18 (1.78-4.19) 4.59 (3.17-7.45) 0.002
Total glucose exposure (g/day) 122.52 ± 32.44 122.38 ± 32.35 122.65 ± 32.90 0.97
D:PCr4h
* 0.64 ± 0.10 0.67 ± 0.11 0.61 ± 0.09 0.006
IL-6 (pg/mL) 7.22 (3.93-13.71) 7.61 (4.66-19.98) 6.42 (3.29-9.63) 0.17
IL-6 Appearance rate^ 23.19 (13.66-59.35) 27.14 (14.12-67.27) 21.90 (13.66-35.01) 0.45
#Measured at month 3; *Measured at month 1; ^IL-6 appearance rate = IL-6*effluent volume/dwell time in minutes.
APD: automated peritoneal dialysis; ATSI: Aboriginal and Torres Strait Islander; CAPD: continuous ambulatory peritoneal dialysis; D:PCr4h: dialysate:plasma
creatinine ratio measured at 4 hours; GFR: glomerular filtration rate; IL-6: interleukin-6; MPI: Maori & Pacific Islander; PD: peritoneal Dialysis.
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0.99-1.00; P = 0.74), was associated with a significantly
shorter time to first peritonitis.
Discussion
The present investigation is the first study to examine
the impact of biocompatible PD solution use on the utility
of IL-6 as a predictor of higher PSTR and peritonitis in
incident PD patients. A statistically significant increase in
dialysate IL-6 concentrations with longer time on PD was
observed whilst the type of PD solution (biocompatible vs.standard) and loss of residual renal function exerted no ef-
fect on its levels. Higher levels of dialysate IL-6 and the
use of standard solutions were predictive of a greater in-
crease in PSTR. The risk of peritonitis was associated with
PD solution (biocompatible solution reduced the risk) but
not baseline IL-6 levels.
An increase in dialysate IL-6 levels with a longer PD
duration has been inconsistently reported by several groups
[8,13,23] including the recently completed GLOBAL fluid
study, which did not show any association between the
duration of PD and dialysate IL-6 levels in incident and
Figure 1 Overall trend of log-transformed dialysate Interleukin-6
concentrations over time in incident peritoneal dialysis patients.
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GLOBAL study were strengthened by a large number of
patients (n = 959), no data were presented pertaining to
a longitudinal trend in dialysate IL-6 levels nor was
there a detailed examination of the impact of biocom-
patible PD solution use on intraperitoneal inflammatory
markers. In contrast, the extension study of the Balnet
trial observed a significant increase in dialysate IL-6
levels from baseline at 24 months in both biocompatible
(143 ± 69.6 pg/mL vs. 57.6 ± 54.5 pg/mL; P < 0.001)
and control groups (121 ± 69 pg/mL vs. 47 ± 31.2 pg/mL;
P < 0.001) [13]. There was no significant difference between
the two groups (P = 0.38). However, the sample size was
small (n = 46), and the potential impact of peritonitis on
dialysate IL-6 levels was not separately explored. The lat-
ter factor might have been important given the discrepant
number of peritonitis episodes between biocompatible
and control groups (19 vs. 6 episodes, respectively), with
a significantly worse peritonitis-free survival in theFigure 2 Trend of log-transformed dialysate Interleukin-6
concentrations over time by type of peritoneal dialysis
solutions received (Biocompatible n = 42; Control n = 46).biocompatible group (P = 0.03). The present investigation
also observed a statistically significant increase in dialysate
IL-6 levels with longer PD duration with a lack of ob-
served difference between biocompatible and standard
types of PD solution. The robustness of the findings
was confirmed by a sensitivity analysis performed in
the peritonitis-free cohort. Nevertheless, there is con-
flicting information about the effect of biocompatible
PD solutions on dialysate IL-6 levels. For instance, the
Bicarbonate/Lactate Study group (n = 92) reported a
significant decrease in dialysate IL-6 levels at six months
(P = 0.01) in the patients who received biocompatible so-
lutions [24]. Although the difference in results might have
stemmed from examining the biocompatible solution
that contained bicarbonate-buffer, another study (n = 55)
examining bicarbonate-buffer based solution reported
comparable dialysate IL-6 levels between biocompat-
ible and standard solution groups [14]. Therefore, the
true effect of biocompatible solutions on the level of
intraperitoneal inflammation, defined by IL-6 concen-
trations, remains uncertain. Furthermore, the rate of
loss of residual renal function exerted no significant
impact on dialysate IL-6 levels. These results are sup-
ported by findings from the GLOBAL study where
urine volume had no significant impact on dialysate
IL-6 levels in incident PD patients (P = 0.2) [10].
Another important observation from the current inves-
tigation was the significant role of an individual’s baseline
IL-6 levels in predicting future levels. Patients with low
baseline IL-6 levels yielded the greatest increase in dialys-
ate IL-6 concentrations over time, whereas the opposing
relationship held true for those with higher baseline IL-6
levels (Additional file 1: Figure S1). This highlights the im-
portance of performing appropriate statistical analyses
to accommodate intra-individual correlation and inter-
individual variation, as adopted in the present study.
Similarly, due to the presence of inter-individual variation
in PSTR levels, a change in PSTR from baseline for
each individual was examined. Significant associations
between increasing PSTR and higher IL-6 levels, the
use of standard PD solutions and longer PD duration
were observed. These results are in keeping with the
findings from the GLOBAL study [10]. An association
between a greater increment in IL-6 with increasing
PSTR (r = 0.306, P = 0.002) was previously reported in
a prospective 12-month longitudinal observational study
(n = 187) in incident PD patients [23]. This study allowed
for patients to receive either biocompatible or standard
solutions, and observed an increase in PSTR in patients
receiving standard solutions over time, unlike those who
were treated using biocompatible solutions who main-
tained a stable PSTR. However, whether PD solution type
and/or dialysate IL-6 levels had differing or independent
effects on PSTR was not examined. Furthermore, the
Table 2 Multilevel linear regression to evaluate the effect of peritoneal dialysis solution type on dialysate interleukin-6
concentrations
All patients (n=88) Peritonitis-free patients (n=56)
Variable Regression coefficient Standard error P values Regression coefficient Standard error P values
PD solution
- Control Reference Reference Reference Reference Reference Reference
- Biocompatible −0.07 0.17 0.68 −0.14 0.22 0.54
Time <0.001 <0.001
- Month 0 Reference Reference Reference Reference Reference Reference
- Month 12 1.18 0.14 <0.001 1.27 0.17 <0.001
- Month 24 1.30 0.17 <0.001 1.40 0.22 <0.001
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the discretion of each patient’s treating physician, thereby
introducing the risk of selection bias. In contrast, the co-
horts from the present study were participants of a RCT
with well-balanced baseline characteristics, at low risk of se-
lection bias and with longer follow-up duration (24 months).
In addition, when PSTR was re-examined in those free of
peritonitis, a consistent association with dialysate IL-6 levels
was observed. These associations are certainly biologically
plausible as higher PSTRs are considered a functionalTable 3 Multilevel linear regression of change in peritoneal s
patients
Full m
Variable Coefficient Standar
Log10 IL-6 0.02 0.0
PD solution
- Control Reference Refer
- Biocompatible −0.05 0.0
PD duration
- 12 month Reference Refer
- 24 month 0.05 0.0
Age 0.0002 0.00
Male −0.03 0.0
BMI (kg/m2):
- <20 Reference Refer
- 20-24.9 0.03 0.0
- 25-30 0.02 0.0
- >30 0.07 0.0
Two-way interaction (PD duration*PD solution)# −0.04 0.0
Ethnicity
- Caucasian Reference Refer
- Asian −0.02 0.0
- ATSI −0.08 0.0
- MPI 0.01 0.0
IL-6: Interleukin-6; PD: peritoneal dialysis; BMI: body mass index; ATSI: Aboriginal an
#Represents interaction between month 12 and use of biocompatible PD solution uconsequence of morphological alterations at the level of the
peritoneal membrane (i.e. peritoneal membrane injury),
which are likely to be a result of or lead to more marked
intraperitoneal inflammation.
Progressive and cumulative peritoneal injury, mediated
by repeated exposures to PD solutions [2], might not
only manifest with changes in the inflammatory milieu
but also increase the risk of developing further problems
(e.g. peritonitis) as the balance of peritoneal homeostasis
and host defence are altered [25]. In this respect the IL-6olute transport rate in incident peritoneal dialysis
odel Final model
d error P values Coefficient Standard error P values
06 0.002 0.02 0.006 0.004
ence Reference Reference Reference Reference
2 0.005 −0.05 0.02 0.005
ence Reference Reference Reference Reference
1 <0.001 0.05 0.01 <0.001
07 0.74
2 0.06
0.11
ence Reference
6 0.59
6 0.71
6 0.25
1 0.008 −0.04 0.01 0.007
0.31
ence Reference
2 0.44
5 0.09
4 0.74
d Torres Strait Islander; MPI: Maori and Pacific Islander.
se; interaction term from month 24 omitted because of collinearity.
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controlling host defence and leukocyte trafficking dur-
ing infection [6,26]. In fact, a retrospective observa-
tional study of incident PD patients (n = 31) receiving
standard solutions reported higher baseline dialysate
IL-6 concentrations in patients who developed peritonitis
(58.4 ± 12.6 pg/mL) compared to those who remained
peritonitis-free (20.3 ± 8.7 pg/mL, P = 0.07) [8]. The dif-
ference however did not reach statistical significance, and
the study was limited by its small sample size and single-
centre design. Similar to their findings, a median dialysate
IL-6 concentration was greater in those who experienced
peritonitis in the present study, but was not statistically
significant when compared to those who did not develop
peritonitis. Furthermore, only the use of standard PD so-
lutions, and not baseline IL-6, was predictive of shorter
time to first peritonitis. These findings support the results
from pre-clinical trials where the use of biocompatible
solutions has been associated with an improvement in
host cell defence [27]. The mechanisms contributing to
the beneficial effect of biocompatible solutions are
clearly complex but its ‘protective effect’ may extend
beyond improved preservation of the peritoneal mem-
brane. These beliefs have been challenged by findings
from a recent observational study that reported a shorter
time to first peritonitis with the use of biocompatible solu-
tions [28]. However, this study has several limitations.
These include a risk of indication bias with residual con-
founding, relatively low usage of biocompatible solutions
in the cohort suggestive of underlying selection bias, and
classifying biocompatible solutions from different manu-
facturers with varying GDP content in the biocompatible
group which could have compromised the beneficial effect
from the use of solutions that are truly low in their GDP
content. On the other hand, although the balANZ trial
was able to clearly demonstrate a lowered risk of periton-
itis with the use of biocompatible solutions, it was one of
the secondary outcomes measured during the trial [17,20].
Therefore, in order to evaluate the true effect of biocom-
patible solutions on peritonitis risk, a well designed, multi-
center, multinational RCT adequately powered to examine
peritonitis as a primary outcome is needed.
The present study is strengthened by its long follow-up
duration in comprehensively described participants of an
RCT. It is one of the largest longitudinal studies to date ex-
ploring the utility of IL-6 in predicting important patient-
level clinical outcomes and the influence of biocompatible
PD solution use. Also, given the cause-and-effect relation-
ship between peritonitis and IL-6 levels, a sensitivity ana-
lysis including only peritonitis-free patients was performed
to confirm the robustness of the findings.
However, the conclusions that can be drawn from the
study are challenged by several limitations. First, the
balANZ trial was a RCT with primary outcome measureof residual renal function decline, rather than a biomarker
study. Therefore, the study design did not account for
potential biological and pre-analytical sources of varia-
tions of IL-6, which could have affected the measured
results. Second, the baseline PSTRs were not true baseline
values as they were obtained at one month after study
commencement. Thirdly, by selecting patients who had
completed the 24-month follow-up, this might have intro-
duced the risk of selection bias. Fourthly, some of the risk
factors associated with a shorter time to peritonitis, such
as educational level, [29] were not available and could
not be adjusted for in the relevant analyses. And lastly,
although it is one of the largest studies to date, the size
is relatively small and may have increased the chance
of Type II statistical error especially when comparing the
outcomes between biocompatible and control groups.
Conclusions
In conclusion, dialysate IL-6 concentration increased with
longer time on PD and was an independent and significant
predictor of increasing PSTR. The type of PD solution did
not influence dialysate IL-6 concentration levels. Standard
PD solution use, but not baseline IL-6 levels, was predictive
of shorter time to first peritonitis. Future studies should
aim to identify the causes of higher dialysate IL-6 levels and
to validate the use of IL-6 as a potential monitoring tool
with an aim to assist in risk stratifying PD patients at
risk of increasing PSTR.
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Australian Centres: G Rangan, L Liew, Blacktown Hospital,
Sydney (NSW); H Kulkarni, U Steinwandel, Fremantle
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